CAMBRIDGE, Mass.--(BUSINESS WIRE)--Omega Therapeutics™, a company pioneering a new category of genomic medicine through epigenomic programming, today announced the completion of an $85 million ...

Next-generation LumenX platform combines more power and pins to significantly expand LumenX device support library, future-proof customer investments and lower the cost of ownership for global ...

REDMOND, Wash., November 17, 2025--(BUSINESS WIRE)--Data I/O Corporation (NASDAQ: DAIO), the leading global provider of data programming and security provisioning solutions for microcontrollers, ...

We may earn revenue from the products available on this page and participate in affiliate programs. Learn more › TL;DR: Take your coding to the next level with Microsoft Visual Studio Professional ...

Josh Haas, left and Emmanuel Straschnov, right are the cofounders and co-CEOs of no-code app development platform Bubble, which raised $100 million on Wednesday. In a world that lives and thrives ...

Intel Parallel Studio XE and Cluster Studio brings parallel computing tools to Linux and Microsoft Visual Studio developers. The compilers support Intel's Parallel Building Blocks and the Fortran ...

The U.S. Food and Drug Administration (FDA) has issued draft guidance on its “Platform Technology Designation Program,” which aims to streamline drug development, manufacturing, and marketing ...

Omega’s platform enables controllable and tunable epigenomic programming. It will provide patients and physicians with therapeutic alternatives to gene editing and gene therapy while offering the ...

New LumenX2 programming platform engineered with more capabilities enables significant expansion of LumenX algorithm library future-proofing customers programming requirements Data I/O Corporation ...